Klemens Lustig

666 total citations
14 papers, 303 citations indexed

About

Klemens Lustig is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Klemens Lustig has authored 14 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Cancer Research and 2 papers in Surgery. Recurrent topics in Klemens Lustig's work include Protease and Inhibitor Mechanisms (3 papers), Fibroblast Growth Factor Research (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Klemens Lustig is often cited by papers focused on Protease and Inhibitor Mechanisms (3 papers), Fibroblast Growth Factor Research (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Klemens Lustig collaborates with scholars based in Germany, United States and Switzerland. Klemens Lustig's co-authors include Peter Ellinghaus, Sylvia Grünewald, Holger Hess‐Stumpp, Mélanie Héroult, Stephan Schäfer, Hendrik Milting, R. Kast, Martina I. Klein, Wiebke Janssen and Charlotte Kopitz and has published in prestigious journals such as International Journal of Cancer, European Respiratory Journal and Cardiovascular Research.

In The Last Decade

Klemens Lustig

14 papers receiving 298 citations

Peers

Klemens Lustig
Yuichi Shinozaki Japan
Jessica D. Dietz United States
Sara Tommasi Australia
Jens‐Kerim Ergüden Germany
Michael W. Lago United States
Jatinder Singh United States
Yunfeng Li China
Annika Westin Eriksson Sweden
Lai Wang China
Miljenko V. Panajatovic Switzerland
Yuichi Shinozaki Japan
Klemens Lustig
Citations per year, relative to Klemens Lustig Klemens Lustig (= 1×) peers Yuichi Shinozaki

Countries citing papers authored by Klemens Lustig

Since Specialization
Citations

This map shows the geographic impact of Klemens Lustig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klemens Lustig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klemens Lustig more than expected).

Fields of papers citing papers by Klemens Lustig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klemens Lustig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klemens Lustig. The network helps show where Klemens Lustig may publish in the future.

Co-authorship network of co-authors of Klemens Lustig

This figure shows the co-authorship network connecting the top 25 collaborators of Klemens Lustig. A scholar is included among the top collaborators of Klemens Lustig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klemens Lustig. Klemens Lustig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Unterschemmann, Kerstin, Alexander Ehrmann, Klemens Lustig, et al.. (2020). Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease. American Journal of Physiology-Renal Physiology. 320(1). F61–F73. 6 indexed citations
2.
Grünewald, Sylvia, Oliver Politz, Sebastian Bender, et al.. (2019). Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International Journal of Cancer. 145(5). 1346–1357. 72 indexed citations
3.
Härter, Michael, Martina Delbeck, Klemens Lustig, et al.. (2018). Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure. European Journal of Medicinal Chemistry. 163. 763–778. 11 indexed citations
4.
Lobell, Mario, Dirk Brohm, Hartmut Schirok, et al.. (2018). Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor. ChemMedChem. 13(5). 437–445. 40 indexed citations
5.
6.
Nagelschmitz, Johannes, Stephan Schwers, Franz von Nussbaum, et al.. (2014). The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases. European Respiratory Journal. 44(Suppl 58). 3416–3416. 5 indexed citations
7.
Muenster, Uwe, Thomas Backensfeld, Thomas Kuhlmann, et al.. (2011). Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): Tools to predict in vivo bioavailability from orally applied drug suspensions. European Journal of Pharmaceutics and Biopharmaceutics. 78(3). 522–530. 12 indexed citations
8.
9.
Urbahns, Klaus, et al.. (2010). Glycine amides as PPARα agonists. Bioorganic & Medicinal Chemistry Letters. 20(11). 3376–3379. 4 indexed citations
10.
Vakalopoulos, Alexandros, Carsten Schmeck, Hilmar Bischoff, et al.. (2010). Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(1). 488–491. 17 indexed citations
11.
Griebenow, Nils, Lars Bärfacker, Heinrich Meier, et al.. (2010). Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(19). 5891–5894. 13 indexed citations
12.
Schäfer, Stephan, Peter Ellinghaus, Wiebke Janssen, et al.. (2009). Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovascular Research. 82(1). 30–39. 55 indexed citations
13.
Urbahns, Klaus, Michael Härter, Delf Schmidt, et al.. (2007). Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides. Bioorganic & Medicinal Chemistry Letters. 17(22). 6151–6154. 17 indexed citations
14.
Clement, Bernd, Klemens Lustig, & Daniel M. Ziegler. (1993). Oxidation of desmethylpromethazine catalyzed by pig liver flavin-containing monooxygenase. Number and nature of metabolites.. Drug Metabolism and Disposition. 21(1). 24–29. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuichi Shinozaki Breakdown of academic impact, for papers by Jessica D. Dietz Breakdown of academic impact, for papers by Sara Tommasi Breakdown of academic impact, for papers by Jens‐Kerim Ergüden Breakdown of academic impact, for papers by Michael W. Lago Breakdown of academic impact, for papers by Jatinder Singh Breakdown of academic impact, for papers by Yunfeng Li Breakdown of academic impact, for papers by Annika Westin Eriksson Breakdown of academic impact, for papers by Lai Wang Breakdown of academic impact, for papers by Miljenko V. Panajatovic
Rankless by CCL
2026